Amarin Corp Plc (AMRN)

[jessellivermore]

About the EPA/statin PCI paper..

Sorry to disappoint several of you enthusiasts, I do not read much of importance into the study. The study confines itself to the problem of heart attacks after coronary artery catheterizations, which are common. The study says that adding EPA to statins while preforming percutaneous coronary interventions (PCI) lowers post PCI MIs which are called type iv.

The post PCI ivs are the result of plaque injury during the PCI and the large lipid containing plaques with slow flow through the vessel are most risky. EPA does lower the post PCI resistance to flow through the vessel and that is probably the reason it works, not plaque stabilization. The exact way EPA decreases type iv MIs is not fully understood, but EPA's known effects on platelets(decreases adherence) and anti inflammatory effects are probably involved. Basically anything that increases flow should cut the chance of getting an MI in this scenario.

This is important for the Interventional Cardiologists and for catheterizations, but not very important or germane to the general problem of CVD risk in atherosclerosis and T2DM

":>) JL